Addus HomeCare provides personal care, home health and hospice services to Medicaid and other government-funded recipients, delivered largely through its home-based caregiver workforce. Its moat is less about the service itself than about scale in a fragmented field: a network across many states that is hard for small local agencies to match in state contract bidding and in recruiting and retaining caregivers. The main growth driver is the demographic shift toward home-based care for an aging population, which pushes more Medicaid spending toward in-home services and away from institutions. At a P/E of 20.0 and a forward P/E of 15.2, the market is pricing in earnings growth, and with revenue growing 8.0% and an operating margin of 9.7%, the case rests on margin expansion as much as top-line growth. Reimbursement rates set by states and the cost of labor are the variables that most often break this kind of model, so that is where the deeper work should start.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 19 Oct 2026, 17:05 CEST | Fair value | $113 | $152 | $116 |
| 19 Oct 2026, 17:05 CEST | Rating | Fairly valued | first publication | $116 |
| 15 Oct 2026, 00:00 CEST | Fair value | $152 | $158 | $115 |
| 11 Oct 2026, 00:00 CEST | ACCE price target | $122 | first publication | $114 |
| 10 Oct 2026, 00:00 CEST | Fair value | $158 | $141 | $114 |
| 29 Sept 2026, 00:00 CEST | Fair value | $141 | $142 | $113 |
| 27 Sept 2026, 00:00 CEST | Fair value | $142 | $144 | $113 |
| 19 Sept 2026, 00:00 CEST | Fair value | $144 | $146 | $118 |
| 13 Sept 2026, 00:00 CEST | Fair value | $146 | $148 | $117 |
| 11 Sept 2026, 00:00 CEST | Fair value | $148 | $149 | $119 |
Answered from Addus HomeCare Corporation Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| ADUS Addus HomeCare Corporation Common Stock | $121.81 | $113 | 8% above | 21.3x | 9.7% | 63 | 66 |
| MD Pediatrix Medical Group Inc. Common Stock | $29.55 | $23 | 26% above | 13.3x | 20.4% | 69 | 74 |
| BKD Brookdale Senior Living Inc. Common Stock | $10.19 | - | - | - | -349.6% | 26 | 25 |
| GRDN Guardian Pharmacy Services Inc. Class A Common Stock | $39.59 | $23 | 76% above | 38.3x | 30.4% | 67 | 61 |
| SGRY Surgery Partners Inc. Common Stock | $15.90 | $10 | 53% above | - | 2.3% | 33 | 43 |
| ASTH Astrana Health Inc. Common Stock | $38.01 | - | - | 44.7x | 6.9% | 35 | 72 |
| AMN AMN Healthcare Services Inc | $46.82 | $71 | 34% below | 17.9x | 15.6% | 52 | 73 |
Where ADUS ranks against its sector peers on each metric.